Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

DexCom Inc. NASDAQ: DXCM is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to monitor their blood glucose levels.

DexCom Stock Gains from GLP-1 Diabetic Users

Axon Enterprise

Ecolab

BNN Bloomberg reported in July 2023 that the S&P 500 was overvalued by about 8%, according to Cresset Capital Chief Information Officer Jack Ablin. In the eight months since, it's up another 19%, providing plenty of overvalued S&P 500 stocks to avoid.

3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy' List

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

DexCom (DXCM) Upgraded to Buy: What Does It Mean for the Stock?

Catalent

Eli Lilly

Novo Nordisk

Stevanato Group SpA

The diabetes and obesity markets are large and growing, with an estimated total long-term addressable market of $100 billion in the US alone. Denmark's Novo Nordisk and US-based Eli Lilly are leading pharmaceutical companies in the development of GLP-1-based treatments for diabetes and obesity.

International Companies Drive Diabesity Innovation

Dexcom Stock: The diabetes play rallied to new highs this week, topping a new buy point in the wake of the FDA's clearance of a new device.

Diabetes Play Dexcom Tops Buy Point After FDA Clears Device Likely To Be Used For Weight Loss

Investors are optimistic about DexCom's (DXCM) strong product portfolio.

DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?

Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.

Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?

Constellation Energy Corp

Moderna

Micron Technology

Super Micro Computer

AI stocks Super Micro Computer and Micron Technology, two of the top performers in the S&P 500 in 2024, led the way on Monday.

Two Hot AI Stocks Lead S&P 500 Monday

Anheuser-Busch InBev

Investors got a good case of whiplash over the past four years. The pandemic crash of 2020 brought a decade-long bull market to a screeching halt.

More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy'

Blackstone Group

CyberArk Software

Neurocrine Biosciences

Royal Caribbean Cruises

S&P 500 stocks DexCom, Blackstone and Royal Caribbean lead five stocks around buy points after Fed chief Jerome Powell helped buoy markets.

S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

DexCom (DXCM) closed at $134.17 in the latest trading session, marking a -0.41% move from the prior day.

DexCom (DXCM) Stock Sinks As Market Gains: Here's Why

Artivion

Edwards Lifesciences

Shockwave Medical

Transmedics Group Inc

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is It Worth Investing in DexCom (DXCM) Based on Wall Street's Bullish Views?

Abbott Labs

iShares U.S. Medical Devices ETF

Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.

Medical Devices ETF Hits 52-Week High: Stocks to Watch

The latest trading day saw DexCom (DXCM) settling at $133.04, representing a -1.63% change from its previous close.

DexCom (DXCM) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Medtronic

Medtronic is a leading medical device maker that continues to get bigger and more diversified. DexCom's continuous glucose monitoring devices are crucial for diabetics, enabling strong growth.

2 Medical Device Stocks to Buy Hand Over Fist in March

DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.

DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System

A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.

DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?

Here is how DexCom (DXCM) and Ambrx Biopharma Inc. (AMAM) have performed compared to their sector so far this year.

Are Medical Stocks Lagging DexCom (DXCM) This Year?

Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search DexCom, Inc. (DXCM): Here is What You Need to Know

DexCom (DXCM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

DexCom (DXCM) Soars 9.8%: Is Further Upside Left in the Stock?

Dexcom stock popped Wednesday after the FDA cleared its newest body-worn glucose monitor for people who don't require insulin treatment.

Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win

DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.

DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval

Dexcom on Tuesday announced that its new over-the-counter continuous glucose monitor called Stelo has been cleared for use by the FDA.

News for DexCom Stock (DXCM)